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B-cell epitopeene-based vaccine, termed 4pox, which targets four orthopoxvirus proteins (A33,
L1, B5, and A27). Because any subunit orthopoxvirus vaccine must protect against multiple species of
orthopoxviruses, we are interested in understanding the cross-protective potential of our 4pox vaccine target
immunogens. In our current studies, we focused on the A33 immunogen. We found one monoclonal antibody
against A33, MAb-1G10, which could not bind the monkeypox virus A33 ortholog, A35. MAb-1G10 binding
could be rescued if A35 amino acids 118 and 120 were substituted with those from A33. MAb-1G10 has been
shown to protect mice from VACV challenge, thus our ﬁndings indicated a protective epitope differs among
orthopoxviruses. Accordingly, we tested the cross-protective efﬁcacy of a DNA vaccine consisting of A35R
against VACV challenge and compared it to vaccinationwith A33RDNA.Mice vaccinatedwith A35R had greater
mortality and more weight loss compared to those vaccinated with A33R. These ﬁndings demonstrate that
despite high homology between A33R orthologs, amino acid differences can impact cross-protection. Fur-
thermore, our results caution that adequate cross-protection by any pan-orthopoxvirus subunit vaccine will
require not only careful evaluation of cross-protective immunity, but also of targeting of multiple orthopox-
virus immunogens.
Published by Elsevier Inc.IntroductionIn response to the potential threat of variola virus (VARV) or a
genetically modiﬁed poxvirus being accidentally or purposefully re-
leased, there is renewed interest in orthopoxvirus vaccination (Bray and
Buller, 2004; Enserink, 2004; Moore et al., 2006). Additionally, monkey-
pox virus (MPXV) continues to causemorbidity andmortality in areas of
Africa (Parker et al., 2007; Rimoin et al., 2007), and the accidental im-
portation of monkeypox-infected animals recently caused amonkeypox
outbreak in theMidwesternUnited States (Reedet al., 2004). The historic
smallpoxvaccine,Dryvax, is composedof live vaccinavirus (VACV) and is
based on technology developed over 200 years ago by Edward Jenner. A
plaque-puriﬁed VACV grown in cell culture, ACAM2000 was recently
deemed safe and effective by the Food and Drug Administration (Arten-
stein et al., 2005; Monath et al., 2004). Despite being highly protective,
these live-virus smallpox vaccines can be associated with signiﬁcant
adverse events, including spread of the virus to other sites on the body,
including the eye (Lane andGoldstein, 2003), and spread to other people
in close contact to the vaccinee. More serious complications can include
myocarditis, progressive vaccinia, eczema vaccinatum, and even death
(Bray, 2003; Cassimatis et al., 2004; Eckart et al., 2004;Kretzschmaret al.,Fort Detrick, MD 21702. Fax: +1
ooper).
nc.2006; Wharton et al., 2003; Wollenberg et al., 2003). As a result, this
vaccine is contraindicated in large segments of the population, including
the immune compromised and individuals with various dermatological
conditions, such as atopic dermatitis (Bray, 2003). Attenuated versions of
the live-virus vaccine have been generated (e.g., MVA and LC16m8);
however, these attenuated viruses still contain hundreds of genes, many
of which encode for immunomodulatory molecules or molecules with
unknown function. The safety risks posed by these molecules remain
unexplored. In response to these negative aspects of live-orthopoxvirus
vaccines, subunit vaccines consisting of orthopoxvirus genes and/or
proteins are currently under development (Fang et al., 2006; Fogg et al.,
2004, 2007; Heraud et al., 2006; Hooper et al., 2000, 2003, 2007, 2004;
Sakhatskyy et al., 2006, 2008; Xiao et al., 2007).
Our laboratory has developed a candidate gene-based vaccine,
termed 4pox, which targets four orthopoxvirus proteins (A33, L1, B5
andA27). TheA33R, L1R, B5R, andA27L genes encode the four proteins,
A33, L1, B5, and A27. All of these immunogens are highly homologous
(N93%) between VACV, MPXV, and VARV. This vaccine targets both
infectious forms of orthopoxviruses, the mature virion (MV) (L1R and
A27L), and the enveloped virion (EV) (A33R and B5R). MVs and EVs are
antigenically distinct from each other and interact with the cell surface
differently (Moss, 2006; Smith and Vanderplasschen, 1998; Smith
et al., 2002; Vanderplasschen and Smith,1997). MVs are believed to be
involved in host-to-host spread, while EVs are thought to be involved
in intra-host viral dissemination. By targeting both particle types, this
vaccine is designed to reduce input virus (MV), quench intra-host
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the 4pox vaccine using VACV or MPXV genes is capable of protecting
mice and non-humanprimates (NHP) from lethal challengewith VACV
or MPXV (Heraud et al., 2006; Hooper et al., 2000, 2003, 2007, 2004
and J.W. Hooper, unpublished results). Others further conﬁrmed the
protective efﬁcacy of these vaccine target combinations using
recombinant protein (Fogg et al., 2004; Xiao et al., 2007). However, it
remains unclear how well these vaccine immunogens individually
contribute to protection against a heterologous viral challenge.
Because any subunit orthopoxvirus vaccine must protect against mul-
tiple species of orthopoxviruses (e.g., VACV, MPXV, and VARV), we are
interested in understanding the cross-protective potential of our 4pox
vaccine target immunogens. To begin to investigate cross-protection,
we initially focused on the A33R component of the 4pox vaccine.
The VACV A33R open reading frame encodes the A33 protein. A33
is a type II integral membrane protein present as a dimer on the EV
(Roper et al., 1996; Smith and Vanderplasschen, 1998). Some evidence
suggests A33 has a role in facilitating antibody-resistant cell-to-cell
spread of orthopoxviruses (Law et al., 2002). It has also been shown to
interact with other orthopoxvirus proteins, A36R and B5R (Wolffe
et al., 2001; Perdiguero and Blasco, 2006). Although non-essential for
replication (Roper et al., 1998), antibodies against A33 are protective
in vivo (Galmiche et al., 1999; Hooper et al., 2002; Lustig et al., 2005;
Chen et al., 2007). For example, monoclonal antibody (MAb)-1G10 is
capable of passively protecting animals from lethal challenge with
VACV strain WR (Lustig et al., 2005). In addition to being a target of
immunotherapeutics, A33 was identiﬁed as a protective target of
subunit vaccines delivered as DNA or protein, alone or in combination
with other protective immunogens (Fogg et al., 2004, 2007; Galmiche
et al., 1999; Heraud et al., 2006; Hooper et al., 2000, 2003, 2007, 2004;
Sakhatskyy et al., 2008; Xiao et al., 2007). Despite representing a
critical target for therapeutic intervention, the regions of A33 critical
for antibody-mediated protection are unknown. The mechanism by
which antibodies mediate protection is also unclear. Here, we ex-
plored a ﬁnding that an anti-VACV A33 MAb was unable to efﬁciently
cross-react with the MPXV A33 ortholog, A35. This observation al-
lowed us to identify amino acids associated with a protective antibody
epitope on the A33 ortholog. Because a protective epitope differed
among VARV, MPXV and VACV, we also examined the effect that
heterogeneity in the A33molecule had on the cross-protective efﬁcacy
of an A33 ortholog-based DNA vaccine against orthopoxvirus chal-
lenge. Throughout this study we refer to the A33R ortholog genes as
A33RVACV (A33R), A33RoMPXV (A35R), and A33RoVARV (A36R) and the
encoded proteins as A33VACV (A33), A33oMPXV (A35), and A33oVARV
(A36), where “o” designates ortholog.
Results
Interaction of anti-A33VACV MAbs with A33oMPXV
We ﬁrst became interested in the potential impact of A33R hete-
rogeneity on protective immunity after observing that one of our
protective anti-A33 mouse MAbs failed to bind A33oMPXV. In that
experiment, two MAbs against A33VACV, MAb-10F10 and MAb-1G10,
were tested for binding to A33oMPXV by radiolabeled immunoprecipi-
tation analysis (RIPA). As expected, both MAb-1G10 and MAb-10F10
immunoprecipitatedA33VACV; however,MAb-10F10, but notMAb-1G10,
immunoprecipitated A33oMPXV (Fig. 1). To conﬁrm the RIPA data, inter-
action of MAb-10F10, MAb-1G10, and a control antibody MAb-10F5
(anti-L1), was tested for binding to puriﬁed A33VACV and A33oMPXV by
ELISA. Both MAb-1G10 and MAb-10F10 bound to puriﬁed A33VACV; but
only MAb-10F10 was capable of binding to puriﬁed A33oMPXV, even at
the lowest dilution tested (Fig. 1B). The control antibody against ortho-
poxvirus L1 (MAb-10F5) did not interactwith either A33 ortholog. These
ﬁndings demonstrated that protective antibodies to at least oneA33VACV
epitope poorly bind A33oMPXV.Reduction of A33 disrupts the epitope bound by MAb-10F10 and
MAb-1G10
Antibody epitopes can be either linear or dependent upon tertiary
structure (i.e. conformational). To gain insight as to the nature of the
MAb-10F10 and MAb-1G10 antibody epitopes, we investigated the
effect reducing A33VACV had on antibody interactions. To this end,
lysates of COS cells transfected with A33RVACV or empty vector were
either unreduced or reduced with β-mercaptoethanol and subject to
immunoblotting using MAb-10F10 and MAb-1G10. Both MAb-10F10
andMAb-1G10 interactedwith A33 under non-reducing conditions. In
sharp contrast, neither antibody interacted with A33 when the mole-
cule was reduced (Fig. 1C). These ﬁndings strongly suggested that
epitopes bound by MAb-10F10 and MAb-1G10 are conformationally
dependent.
Interaction of anti-A33VACV MAbs with VACV and MPXV-infected cells
Because the epitopes bound by both MAb-1G10 and MAb-10F10
were conformationally dependent (Fig. 1C), we reasoned that while
MAb-1G10 did not bind recombinant A33oMPXV as determined by
ELISA and RIPA, it was possible that this antibody could bind to the
authentic protein expressed in cells infected withMPXV. This could be
due to conformational changes induced when the molecule is loca-
lized in a viral or cellularmembrane or due to interaction(s) with other
viral protein(s), such as an ortholog of the A36VACV or B5VACV mole-
cules (Rottger et al., 1999; Smith et al., 2002; Wolffe et al., 2001;
Perdiguero and Blasco, 2006). Therefore, we examined the capacity of
MAb-10F10 andMAb-1G10 to interact with A33o in cells infected with
VACV, strain IHD-J, or MPXV, strain Zaire79. VACV strain IHD-J was
chosen because this is the strainwe typically use to perform challenge
studies (see below). The A33R from VACV strain IHD-J and strain
Connaught are highly homologous. There are two nucleotide (nt)
changes (A to G at position 276 and G to A at 511). The nt change at 276
is silent and the nt change at 511 results in a V to I substitution at
amino acid position 171 (data not shown). COS cells were infected
with IHD-J or MPXV and 48-h post-infection cells were ﬁxed and
stained with MAb-10F10, MAb-1G10 or a control antibody MAb-3D7
(anti-Hantaan G2), followed by a secondary anti-mouse antibody
conjugated to Alexﬂuor488. MAb-10F10 bound to both VACV- and
MPXV-infected cells (Fig. 1D). In contrast, MAb-1G10 bound VACV-
infected cells, but failed to efﬁciently bind MPXV-infected cells. The
reactivity that was observed with MAb-1G10 was markedly lower
compared to MAb-10F10 and almost below the level of detection
(Fig. 1D). Thus, MAb-1G10 bound poorly to A33oMPXV in assays in-
volving not only recombinant protein, but also authentic protein in the
context of MPXV-infected cells.
Rescue of MAb-1G10 interaction with A33oMPXV
Based on the predicted amino acid sequence, there are eight amino
acid substitutions between A33VACV and A33oMPXV. The A33oMPXV is
also truncated by four amino acids at the carboxy terminus (Fig. 2A).
To determine which amino acid difference(s) disrupted the epitope
bound by MAb-1G10, we initially examined the role of the amino acid
difference at the carboxy terminus of the A33oMPXV. A construct was
generated that encoded A33oMPXV where the carboxy terminal threo-
nine was replaced with the last ﬁve amino acids of A33VACV. This
construct was designated A33RoMP/VACV-Cterm. COS cells were then
transfected with either A33RoMP/VACV-Cterm or A33RVACV and then sub-
jected to RIPA analysis. As shown in Fig. 2B, protein expressed from the
A33RoMP/VACV-Cterm construct was able to interact with theMAb-10F10
and hyperimmune mouse serum; however, it was not bound by MAb-
1G10. These data suggested that the C-terminal amino acid truncation
was not involved in MAb-1G10 binding. We next examined the role of
residues 117, 118, and 120 in MAb-1G10 binding. All three amino acids
Fig. 1. Interaction of MAbs MAb-1G10 and MAb-10F10 with A33VACV or A33oMPXV. A. COS cells were either not transfected (−) or transfected with pWRG/A33R or pMPXV/A33Ro and
labeled with 35S-methionine/cysteine. Cell lysates were then incubated with MAb-10F10 or MAb-1G10. Protein–antibody complexes were precipitated, revolved by SDS-PAGE and
subjected to phosphoimaging analysis. B. ELISAs were performed using puriﬁed A33VACV or A33oMPXV proteins. Serial dilutions of MAb-10F10 (closed squares), MAb-1G10 (closed
triangles) or a control antibody MAb-10F5 (anti-L1) (open circles) were incubated with both proteins then incubated with an anti-mouse secondary antibody conjugated to
horseradish peroxidase. Each point represents an average of two samples±standard deviation. C. COS cells were transfected with pWRG/A33R or empty vector. Cells lysates were
either untreated or reduced with β-mercaptoethanol, resolved by SDS-PAGE, and transferred to nitrocellulose. Samples were then immunoblotted with MAb-10F10 or MAb-1G10
followed by a secondary anti-mouse IgG conjugated to horseradish peroxidase. D. COS cells were infectedwith either VACV, strain IHD-J, or MPXV, strain Z79, for 48 h and ﬁxed. Fixed
cells were incubated with MAb-10F10, MAb-1G10, or MAb-3D7 (anti-Hantaan G2). Cells were then incubated with a secondary anti-mouse antibody conjugated to Alexﬂuro488.
Coverslips were mounted onto glass slides in mounting medium containing DAPI nucleic acid stain and the edges of plaques were imaged on a ﬂuorescence microscope.
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forming a construct designated A33RoMP117–120. COS cells were then
transfected with plasmids expressing mutant A33RoMP117–120 or
A33RVACV and subjected to RIPA analysis. As shown in Fig. 2C, protein
expressed from the mutated A33RoMPXV construct could interact withMAb-1G10. These data indicated that amino acids 117, 118, and 120
were involved in the epitope bound by MAb-1G10.
We next investigated the individual contribution of each of the
three amino acids to MAb-1G10 binding. A33RoMPXV constructs were
generated containing single changes (K117Q, S118L, and E120S) and
Fig. 2. Rescue of MAb-1G10 binding to A33oMPXV. A. Comparison of the predicated amino acid sequences of A33VACV (strain Connaught), A33oMPXV (strain Zaire79) and A33oVARV
(Bangladesh). Amino acids 1–31 contain the predicted N-terminal cytoplasmic tail, amino acids 32–57 contain the predicted signal sequence/transmembrane, amino acids 58–185
contain the extracellular domain (Roper et al., 1996). There are also two predicted N-linked glycosylation sites at positions 125 and 135 (Roper et al., 1996). The A33 from VACV strain
Connaught is identical to that of VACV strainWR. B. COS cells were transfectedwith pWRG/A33R or pWRG/A33RoMP-VACV-Cterm and subjected to RIPA. Cell lysates were incubatedwith
MAb-10F10, MAb-1G10 or, for a positive control, hyperimmune mouse serum. RIPA was performed as described in Fig. 1A. C. COS cells were transfected with pWRG/A33R or pWRG/
A33RoMP117–120 and subjected to RIPA. Cell lysates were incubated with MAb-10F10, MAb-1G10, and a control antibody MAb-7D11 (anti-L1). RIPA was performed as described
in Fig. 1A.
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determine if these changes were sufﬁcient to allow an interaction by
MAb-1G10, COS cells were transfected with A33RVACV and A33RoMPXV
and the mutant constructs and analyzed by ﬂow cytometry. As deter-
mined by the forward scatter, MAb-1G10 and MAb-10F10 both
interacted with surface-expressed A33VACV (Fig. 3A). MAb-10F10 also
efﬁciently interactedwith A33oMPXV. Consistent with our observations
of MPXV-infected cells (Fig. 1D), we observed a slight interaction
between MAb-1G10 and A33oMPXV. Similar to data shown in Fig. 2C,
a change in all three amino acids rescued MAb-1G10 interaction
(Fig. 3A). Furthermore, analysis of the A33oMPXVmutants revealed that
changes at position S118L and E120S and double changes at positions
K117Q/S118L and S118L/E120S could also rescue MAb-1G10 interac-
tion. No sample interactedwith the control antibody,MAb-10F5. These
ﬁndings suggested that amino acids 118 and 120 play a critical role in
MAb-1G10 binding.
If the amino acids 118 and 120 were critical for MAb-1G10
interaction, we predicted MAb-1G10 should interact with another
orthopoxvirus A33 ortholog that is homologous to VACV at these sites,such as A33oVARV. Thus, the ability of MAb-1G10 to interact with
A33oVARV was examined by ﬂow cytometry. COS cells were transfected
with DNA-encoding A33RVACV or A33RoVARV, and 48 h post-transfec-
tion, cells were incubated with MAb-10F10, MAb-1G10, or the nega-
tive control antibody, MAb-10F5. As demonstrated by the forward
scatter, both MAb-10F10 andMAb-1G10 interacted with A33oVARV to a
degree similar to that observed with VACVA33 (Fig. 3B). These results
supported our conclusion that amino acids 118 and 120 are involved in
MAb-1G10 antibody interaction with A33o.
Cross-protective efﬁcacy of A33RoMPXV DNA against VACV challenge
Because our ﬁndings indicated protective epitopes on the A33o
molecule differ among MPXV, VARV, and VACV, we hypothesized that
vaccinationwithA33R (or ortholog)DNA fromoneorthopoxvirusmight
not efﬁciently cross-protect against heterologous viral challenge. To test
this hypothesis, we investigated the capacity for a DNA vaccine con-
sisting of either A33RVACV or A33RoMPXV to protect mice from lethal
challengewithVACV.MicewerevaccinatedwithDNAencoding-A33RVACV
Fig. 3. Characterization of the amino acids involved in MAb-1G10 binding. A. COS cells were transfected with pWRG/A33R, pMPXV/A33Ro or the mutagenized constructs. Next, a
portion of transfected COS cells (∼1×106 cells per sample) were incubated with MAb-10F10 (solid black line), MAb-1G10 (dashed grey line) or a control antibody MAb-10F5 (solid
grey area) followed by a secondary anti-mouse antibody conjugated to an Alexﬂuro488 ﬂuorochrome. Antibody interactions with surface-expressed proteins were then analyzed by
ﬂow cytometry. Each analysis scanned a total of 10,000 cells/sample. B. COS cells were transfected with pWRG/A33R or pVAR/A33Ro. 48 h post-transfection, antibody interactions
with surface-expressed A33VACV or A33oVARV were assessed by ﬂow cytometry using MAb-10F10 (solid black line), MAb-1G10 (dashed grey line), or a negative control antibody MAb-
10F5 (solid grey area), as described above.
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bardment using a gene-gun. Two weeks after the ﬁnal vaccination,
antibody responses against A33VACV or A33oMPXV were evaluated by
ELISAwith puriﬁed A33VACV or A33oMPXV proteins.Mice vaccinatedwith
either A33RVACV or A33RoMPXV elicited a similar antibody response
against their respective antigen,withgeometricmean titers (GMT)of 3.7
and 3.2, respectively. Three weeks after the ﬁnal vaccination, A33RVACV
and A33RoMPXV vaccinated mice were challenged intranasally with
2×106 pfu of VACV, strain IHD-J. Control mice vaccinated three times at
3-week intervals with negative control DNA or once by tail scariﬁcation
with live VACV, strain Connaught, were also included in the challenge.
The percent weight loss for survivors from each group relative to thegroup startingweight and thepercent survival for each group are shown
(Fig. 4A). As expected, weights in the negative control group declined
drastically starting at day two and by day seven, all mice succumbed to
infection.Mice vaccinatedwith live virus exhibited only amoderate loss
inweight that was ∼10% below the starting weight at its maximum and
returned to starting levels by day nine. In contrast, mice vaccinatedwith
DNA-encoding A33RoMPXV began dropping weight starting on day two.
This drop continued until day 11. In this group, 40% of the mice suc-
cumbed to infection. Mice vaccinated with DNA-encoding A33RVACV
exhibited less severe signs of disease. Weight loss for this group of mice
began on day four, peaked on day ﬁve and began to increase on day six.
This weight loss was never as high as the group administered with
Fig. 4. Protection against heterologous viral challenge. A. Mice were vaccinated by gene-gun three times at 3-week intervals with DNA encoding either A33RVACV or A33RoMPXV. Three
weeks after the last vaccination, micewere challenged intranasally with 2×106 pfu VACV strain IHD-J. This dose represents 3 LD50 (Hooper et al. 2003). Mice vaccinatedwith live virus
(VACV, strain Connaught) by tail scariﬁcation or with negative control DNAwere also included in the challenge as controls. Weights of each group were monitored daily for 21 days.
Data for groupweights were graphed using Excel and the percent weigh loss relative to starting groupweight for survivors was plotted. The percent survival was also plotted for each
group. B. Antibody responses in individual mice were determined by ELISA. Sera from A33RVACV (black bars) and A33RoMPXV (grey bars) vaccinated mice were serially diluted 10-fold
and evaluated by ELISAwith both puriﬁed A33 (left panel) or A35 (right panel). The b symbol denotes readings that were below the limits of detection. Mice succumbing to infection
are denoted by the symbol. C. COS cells were transfected with pWRG/A33R, pMPXV/A33Ro, pVARV/A33Ro, or the A33RoMPXV mutant, pWRG/A33RoMP117–120. Antibody interactions
with surface-expressed A33owere assessed by ﬂow cytometry using MAb-10F10 (dark grey area), sera frommice vaccinated with A33RVACV (black line) and A33RoMPXV DNA (dashed
grey line), or sera from unvaccinated mice (light grey area).
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25J.W. Golden, J.W. Hooper / Virology 377 (2008) 19–29A33RoMPXV DNA. Only 20% of the A33RVACV vaccinated mice died. Addi-
tionally, weights of mice vaccinated with A33RVACV returned to starting
levels by day 21, whereas weights of mice vaccinated with A33RoMPXV
that survived remained, on average, ∼15% below their starting weight.
We performed an ELISA using sera from each vaccinated animal to
determine the cross-reactivity of antibodies frommice vaccinatedwith
A33RoMPXV or A33RVACV DNA against homologous and heterologous
protein (Fig. 4B). Antibodies from mice vaccinated with A33RVACV did
not interactwith theA33oMPXV antigen (GMT=2.7) as efﬁciently as they
did with homologous VACVA33 antigen (GMT=3.7). Similarly, anti-
bodies from mice vaccinated with A33RoMPXV did not interact with
A33VACV antigen (GMT=2.1) as efﬁciently as they did with homologous
A33oMPXV antigen (GMT=3.2). We also observed that animals vacci-
nated with A33RVACV DNA that succumbed to challenge had the lowest
antibody responses against A33VACV, suggesting low titers in this group
led to poor survivability. Interestingly, some A33RoMPXV vaccinated
mice survived challenge yet had cross-reactive anti-A33 responses
below the level of detection. In contrast, one mouse vaccinated with
A33RoMPXV DNA that died from challenge had the strongest cross-
reactive response. These ﬁndings indicated that there is reduced cross-
reactivity of serum antibodies between A33 orthologs. Our data also
indicate that the level of cross-reactivity of antibodies from
A33RoMPXV-vaccinated mice with the A33VACV molecule did not
correlate with the survivability of animals.
We next investigated if amino acids 117,118, and 120 played a role in
the poor cross-reactivity of antibodies from mice vaccinated with
A33RVACVDNAwithA33oMPXVprotein. To this end, cellswere transfected
with A33RVACV, A33RoVARV, A33RoMPXV or the mutant A33RoMPXV that
had nucleotide changes that altered amino acids at positions 117, 118,
and 120 into those of A33VACV. Transfected cells were then incubated
with MAb-10F10 or pooled sera from unvaccinated mice and mice vac-
cinated with A33RVACV or A33RoMPXV DNA. Antibody interactions with
the various A33 orthologs were then assessed by ﬂow cytometry. We
observed an interaction between MAb-10F10 and each ortholog, de-
monstrating that cells were efﬁciently transfected with each molecule.
Serum antibodies from mice vaccinated with A33RoMPXV DNA reacted
efﬁciently with A33oMPXV protein, but a marked reduction in interac-
tion was observed with the A33VACV and A33oVARV molecules (Fig. 4C).
Conversely, serum antibodies from A33RVACV DNA-vaccinated mice
reacted efﬁciently with A33VACV and A33oVARV protein, but less so with
A33oMPXV. However, interactions of serum antibodies from mice vac-
cinated with A33RVACV DNAwere improved if A33oMPXV amino acids at
positions 117, 118, and 120 were changed to those of A33VACV (Fig. 4C).
These data conﬁrm the ELISA ﬁndings (Fig. 4B) and showed that mice
vaccinatedwith DNA encoding each ortholog interacted best with their
respective proteins. Furthermore, the improved interactions of anti-
A33VACV serum antibodies with mutant A33oMPXV molecules strongly
suggests that amino acids 117, 118, and 120 play a critical role in A33o
antibody epitopes in mice vaccinated with A33Ro DNA.
Discussion
Amino acids involved in protective antibody binding
Several studies have found that antibodies are critical for protec-
tion against secondary orthopoxvirus infections (Edghill-Smith et al.,
2005; Panchanathan et al., 2005, 2006, 2008). In responses to these
ﬁndings, recent investigations have sought to identify critical antibody
epitopes of several poxvirus subunit vaccine targets, including B5 and
L1 (Aldaz-Carroll et al., 2005a,b; 2007; Su et al., 2007). The A33 protein
is a valuable target of subunit vaccines and immunotherapeutics (Fang
et al., 2006; Fogg et al., 2004; Galmiche et al.,1999; Heraud et al., 2006;
Hooper et al., 2000, 2003, 2002, 2004; Lustig et al., 2005; Xiao et al.,
2007). However, little is understood regarding antibody domain(s)
critical for protection, or the mechanism of protection. By capitaliz-
ing on the inability of a MAb against A33VACV to efﬁciently bind theA33oMPXV ortholog, we were able to determine that at least one
antibody-binding domain involves amino acids 118 and 120 (Figs. 2
and 3). This ﬁnding was based on the observation that changing the
A33oMPXV amino acids at either of these positions rescued MAb-1G10
binding (Figs. 2 and 3). Additionally, we showed that MAb-1G10
bound A33oVARV, whose amino acids are identical to those of A33VACV
at these positions (Fig. 3B). Our conclusion that this region of A33 is
involved in protective immunity is based on the ﬁnding that MAb-
1G10 is a protective antibody capable of passively protecting animals
from lethal VACV challenge (Chen et al., 2007; Lustig et al., 2005).
Our ﬁndings did not discern whether amino acids 118 and 120
directly interact with MAb-1G10 or function indirectly by impacting
the conformation of the physical epitope. However, ﬁndings in the
literature support the conclusion that this region constitutes a physical
antibody-binding domain. Heraud et al. reported that serum anti-
bodies from NHP vaccinated with A33RoMPXV DNA and/or protein
reacted with short (15-mer) peptides homologous to regions of the
A33oMPXV protein that contained amino acids 117,118, and 120 (Heraud
et al., 2006). In that study, we suggested that this region is important
for protective antibody interaction. However this conclusion was not
based on experimental evidence and it was not determined if anti-
bodies binding to this regionwere in fact protective or just part of the
polyclonal antibody pool generated against A33oMPXV. Using these
same peptides, we found that NHPs vaccinated by gene-gun with
A33RoMPXV DNA also developed anti-A33 responses targeting this
region of the A33o molecule (Golden, J.W. and Hooper, J.W., un-
published observations). Recently, Chen et al. developed chimpanzee/
human hybrid anti-A33 antibodies that can provide in vivo protection
against orthopoxvirus challenges (Chen et al., 2007). The authors de-
termined that the region involved in antibody interaction encom-
passed amino acids 99 and 185, which includes the amino acids
identiﬁed in our study. In another study, Roper et al. observed that two
anti-A33VACV MAbs, MAb 4 and MAb 105, failed to interact with ectro-
melia virus (ECTV) (Roper et al., 1996). A33oECTV contains the same
amino acids as A33oMPXV at positions 117,118, and 120, suggesting that
perhaps MAb 4 and MAb 105 interact with this same region of A33. It
is curious that antibodies elicited by various experimental means
(NHP vaccinated with protein/DNA or with live virus and mice in-
fected with VACV) all target this region of the A33 protein. Together
these ﬁndings suggest this region of A33 may be a hotspot for pro-
tective antibody interaction. This conclusion is further supported by
the fact that MAb-10F10 is also a protective antibody (Golden, J.W. and
Hooper J.W., unpublished ﬁndings and Hooper et al., 2002), and
competes with MAb-1G10 for binding in competition ELISAs (Hooper,
J.W, and Schmaljohn, A, unpublished ﬁndings).
While MAb-1G10 did not interact with A33oMPXV in the RIPA
(Fig. 1A) or with puriﬁed A33oMPXV by ELISA (Fig. 1B), we did observe a
slight interaction with A33oMPXV by ﬂow cytometry (Fig. 3A) and with
A33oMPXV expressed in MPXV-infected cells (Fig. 1D). This could be
explained by the interaction of A33oMPXV with a viral and/or cellular
membrane, which would be absent in detergent-treated protein (RIPA)
or Escherichia coli-expressed A33 ectodomain (ELISA). In contrast, the
ﬂow cytometry experiment examined surface-expressed A33 bound to
the cellularmembrane (Fig. 3), and in infected cells, themoleculewould
bepresent in both cellular and viralmembrane (Fig.1D). The interaction
of the A33 transmembrane region with a membrane might induce a
conformational shift in the molecule making the epitope more ac-
cessible to MAb-1G10. Additionally, the fact that we observed some
interaction of MAb-1G10 with A33oMPXV makes it likely that more
amino acids are involved in antibody binding. Our ﬁndings also indicate
that the antibody epitope is likely to be conformational, as reduction of
the A33VACV protein disrupted the interaction of both MAb-10F10 and
MAb-1G10 (Fig. 1C). A similar observation was noted by Chen et al., in
that reduction of the VACVA33molecule disrupted interactions of a anti-
A33 chimpanzeeMAb (Chen et al., 2007). Further studies, especially co-
crystallization of the MAb-10F10 and MAb-1G10 FAb fragments bound
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antibody epitope(s). Such information will be a valuable guide for the
development of A33-targeted immunotherapeutics and subunit vac-
cines that would ensure efﬁcient cross-reactivity against
orthopoxviruses.
The mechanism(s) whereby antibodies against A33 protect is not
well understood. There is evidence to suggest that anti-EV antibodies
block EV release from cells, but do not efﬁciently neutralize virus
(Vanderplasschen et al., 1997). Perhaps this region of A33 possesses a
functional domain required for EV release/spread that is blockedbyanti-
A33 antibodies. Alternatively, this regionmay be optimally positioned to
allow bound antibodies to ﬁx complement, leading to virus inactivation.
This latter possibility is supported byﬁndings that, at least in cell culture,
anti-EV antibodies in the presence of complement can disrupt EV
membranes making particles susceptible to neutralization by anti-MV
antibodies (Lustig et al., 2004). Unfortunately, in vivo evidence for this
mechanism is lacking. Clearly, more studies will be required to fully
address the mechanism of protection elicited by anti-A33 antibodies.
Implications for cross-protection
In this study, we examined if differences in the A33 molecule could
affect the cross-protective efﬁcacy of a A33R-based molecular vaccine.
Indeed,weobserved amarked reduction in the capacityof anA33RoMPXV
vaccine to cross-protect againstweight loss after VACV challenge (Fig. 4).
Our data suggest the poor cross-protection was associated with amino
acids117,118, and120, because sera frommice vaccinatedwithA33RVACV
DNA, while reacting poorly with A33oMPXV protein, could interact with
mutant A33RoMPXV containing changes in these amino acids to those of
VACV (Fig. 4C). Curiously, there was not an absolute correlation with
anti-A33oMPXV cross-reactive antibody titers and survivability in mice
vaccinated with A33RoMPXV DNA (Fig. 4B). These ﬁndings suggest that
despite having a high cross-reactive titer, in some animals only a small
portion, if any, of the polyclonal antibodies produced from vaccination
cross-reactedwith a protective epitope(s). Additionally, in some animals
cross-reactivity with VACVA33 was low, yet the animals survived. This
may suggest that despite having low cross-reactivity, a large enough
portion of the polyclonal antibody pool could interact with protective
domains in the A33 molecule to shield the animal from lethal infection.
Alternatively, this result could indicate that a T-cell response is contri-
buting to cross-protection.
Fang et al. have recently shown that mice vaccinated with
A33oECTV, or A33VACV protein in incomplete Freund's adjuvant (IFA)
are protected from ECTV challenge (Fang et al., 2006). Similar to our
ﬁndings, antibodies from vaccinated mice reacted best with homo-
logous protein compared to the heterologous ortholog. However, mice
were completely protected from ECTV challenge regardless of the A33
ortholog used for vaccination. The ECTV challengemodel used by Fang
et al. and the VACV challenge model used here differ not only in the
virus used, but also the dose and route of challenge. Thus, it is difﬁcult
to determine why vaccination with A33 was completely protective in
the ECTV model, whereas vaccination with A33RoMPXV was less
protective than A33 at protecting in the VACV, strain IHD-J model. It is
possible that protection of mice from ECTV challenge does not require
as high of a protective anti-A33 immune response compared to that
required for protection from VACV strain IHD-J, or that the anti-A33
immune response was sufﬁciently potent after vaccination with
puriﬁed protein and adjuvant to afford complete cross-protective
immunity. The IHD-J strain of VACV is known to produce large
amounts of extracellular EV in cell culture (Payne, 1979), and this has
been mapped to a mutation in the A34R gene (Blasco et al., 1993). If
efﬁcient production and spread of IHD-J extracellular EV occurs
in vivo, then a very potent anti-A33 immune response might be
required to protect against VACV, strain IHD-J. It is possible that
heterogenicity in the A33 immunogens used to vaccinate could affect
the response enough to be manifested as a difference in protectiveefﬁcacy. Regardless, the results of our challenge experiment (Fig. 4)
demonstrate that at least in some cases A33 does not provide
complete cross-protection against heterologous challenge.
Other groups have observed poor cross-reactivity of antibodies
against orthopoxvirus vaccine targets. As stated above, this includes
Roper et al. who reported some anti-A33VACV MAbs do not interact
with A33ECTV (Roper et al., 1996). Aldaz-Carroll et al. recently found
that antibodies against B5VACV do not cross-react efﬁciently with the
B5oVARV (Aldaz-Carroll et al., 2007). Thus, inadequacies in cross-
reactivity exist for other orthopoxvirus subunit vaccine targets. To
circumvent cross-protective deﬁciencies and otherwise bolster pro-
tective immunity, several groups, including ours, combined multiple
protective orthopoxvirus immunogens into molecular smallpox vac-
cines. The 4pox molecular smallpox vaccine was designed to target
immunogens associated with both the MV and EV forms of orthopox-
viruses. For redundancy, two targets are present on the MV (L1 and
A27) and two are present on the EV (A33 and B5), as well as on
infected cells (Moss, 2001; Resch et al., 2007; Smith et al., 2002). The
ability for this vaccine to cross-protect against MPXV challenge in
NHPs has been reported (Hooper et al., 2004). Fogg et al. have also
reported that a combination of three of our four VACV immunogens,
VACV-L1, -B5, and -A33, can protect against MPXV challenge in NHPs
when delivered as puriﬁed protein in the presence of an adjuvant
(Fogg et al., 2007). It is likely that in both these NHP studies, anti-
bodies against B5 compensated for poorly cross-reactive anti-A33o
antibodies. From this, we can also hypothesize that a vaccine con-
taining the A33oMPXV might elicit a suboptimal immune response
against VARV, whereas a vaccine containing the A33VACV or A33oVARV
would elicit good anti-A33 responses against VACV and VARV, but not
against MPXV.We are currently evaluating the cross-reactive immune
responses generated in mice vaccinated with the 4pox genes derived
from VACV, MPXV, and VARV. These data will shed light on which
orthopoxvirus gene sequences should be used in a subunit vaccine to
provide the broadest protection. It might also be possible to use
engineered immunogens, such asA33RoMP117–120, to elicit higher levels
of cross-protective immunity against MPXV, VACV and VARV.
Any subunit vaccine against orthopoxviruses must be designed to
protect against several species of orthopoxviruses, including MPXV
and VARV and also genetically modiﬁed poxviruses. In this respect, the
obvious choices of targets for molecular subunit vaccines have been
those that lead to the generation of protective immune responses and
are also highly homologous molecules among the orthopoxvirus
family. Data presented here and elsewhere (Aldaz-Carroll et al., 2007;
Roper et al., 1996) highlight a caveat to this rationale and reveal that
despite high overall homology, slight variations in critical epitopes can
impact the cross-protective efﬁcacy of subunit vaccine targets. Our
ﬁndings caution that adequate cross-protection by any pan-ortho-
poxvirus subunit vaccine will require careful evaluation of cross-
protective immunity. Nevertheless, redundant targeting of multiple
orthopoxvirus immunogens will likely compensate for any deﬁcien-
cies in cross-reactivity that may occur for individual immunogens.
Materials and methods
Cells, viruses, and monoclonal antibodies
VACV Connaught vaccine strain (derived from the New York City
Board of Health strain), VACV strain IHD-J (obtained from Dr. Alan
Schmaljohn), and MPXV strain Zaire79 (obtained from Dr. John
Huggins)were allmaintained inVEROcell (ATCCCRL-1587)monolayers
grown in Eagleminimal essentialmedium (EMEM), containing 5%heat-
inactivated fetal bovine serum (FBS) (Hyclone; Logan, UT),1% antibiotics
(100 U/ml penicillin, 100 μg/ml of streptomycin, and 50 μg/ml of gen-
tamicin), 10 mM HEPEs (cEMEM). COS-7 (COS) cells (ATCC CRL-1651)
were used for transient expression experiments and were also main-
tained in EMEM.
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were used in these studies (Hooper et al., 2000). The murine MAb-
7D11 and MAb-10F5 recognize the poxvirus MV protein L1 (Hooper
et al., 2000; Wolffe et al., 1995). All MAbs were produced at USAMRIID
and propagated in the USAMRIID hybridoma facility.
Radiolabeled immunoprecipitation (RIPA)
The RIPA method was described previously (Hooper et al., 2000).
Brieﬂy, COS cells were transfected with pWRG/A33R pMPXV/A33Ro or
mutant A33Ro constructs as indicated using Fugene6 (Roche;
Indianapolis, IN). The pWRG vector has been described elsewhere
(Schmaljohn et al., 1997). By 24-h post-transfection, COS cells were
labeled with 35S-methionine/cystine for 4 h and lysed using 4% zwit-
tergent buffer (4% zwittergent, 0.5 M NaCL, 1 mM EDTA and 10 mM
Tris [pH 8.0]). Cell lysates were incubated as indicated with two MAbs
known to interact with A33RVACV, MAb-1G10 andMAb-10F10 (Hooper
et al., 2000) or a control antibodyMAb-7D11 that interacts with L1 (Su
et al., 2007; Wolffe et al., 1995). Protein–antibody complexes were
immunoprecipitated using protein A. Immunoprecipitated lysates
were analyzed by SDS-PAGE on 4–12% gels. Resolved gels were dried,
placed on a phosphoimager screen, and examined on a Cyclone Phos-
phoimager reader (Packard Instruments; Groningen, Netherlands).
Puriﬁcation of orthopoxvirus proteins
Puriﬁcation of A33RoMPXV produced in E. coli was described pre-
viously (Heraud et al., 2006). Puriﬁed A33VACV was prepared in E. coli
bymethods similar to those previously reported (Heraud et al., 2006);
however, a new plasmid, pET21-A33RΔTM, contained the A33RVACV
open reading frame with the predicted transmembrane regions (i.e.,
60–181) removed. A detailed description of the plasmid construction
and protein puriﬁcation procedure will be published elsewhere.
Protein ELISA
Puriﬁed VACV antigens, A33 or A33oMPXV (50 ng/well), were diluted
in 0.1M carbonate buffer [pH 9.6] and plated in duplicate in thewells of
a high-binding 96-well plate (Corning, Corning, NY). After 24 h at 4 °C,
wells were blocked with phosphate-buffered saline (PBS) containing
0.05% tween (PBS-T) and 5% milk. Hybridoma supernatant containing
MAbs against A33VACV, MAb-10F10, andMAb-1G10 or against VACV-L1,
MAb-10F5, were diluted twofold in blocking buffer (starting at 1:100)
and incubated for 1 h with the puriﬁed proteins. Plates were washed
four times inPBS-Tand incubatedwith ananti-mouse IgGconjugated to
horseradish peroxidase (Sigma) (1:1000) for 1 h at 37 °C. Plates were
washed again four times in PBS-T and 100 μL of 2,2′-azinobis-3-
ethylbenzthiazoline-6-sulfonic acid (ABTS) substrate (KPL, Gaithers-
burg, MD) was added to each well. Reactions were stopped by adding
100 μl of ABTS stop solution of 5% (w/v) sodium dodecylsulfate to each
well. The optical density (O.D.) at 405 nm was read on a Spectramax
ELISA plate reader (Molecular Devices; Sunnyvale, CA). Each reaction
represents the average of two reactions±standard deviation.
End-point antibody ELISA titers from vaccinated mice
Puriﬁed A33VACV or A33oMPXV (50 ng/well) diluted in 0.1 M carbo-
nate buffer [pH 9.6], were plated in duplicate in the wells of a high-
binding 96-well plate (Corning). To control for background, plates
were also coated with a negative control antigen, botulinum toxin
(50 ng/well) (recombinant botulinum toxin puriﬁed from E. coli pro-
vided by Alphavax Inc.). Plates were blocked for 1 h with PBS-T and 5%
milk. The indicated antibodies or mouse sera were serially diluted
tenfold (starting at 1:100) in PBS-T containing 5% milk and E. coli
lysate. Serum dilutions were incubated with the antigens for 1 h at
37 °C. Subsequent steps were identical to those described above. End-point-titers were determined as the highest dilution with an absor-
bance value greater than the mean absorbance value from negative
control plasmid-vaccinated animals plus three standard deviations.
Immunoﬂuorescence of virus-infected cells
5–15 pfu of VACV, strain IHD-J, or MPXV, strain Zaire79, diluted in
100 μl of EBME were adsorbed onto conﬂuent monolayers of COS cells
on coverslips for 1 h at 37 °C. After adsorption, the inoculum was
removed and a 1:1 mixture (1 ml total volume/well) of 3.0% methyl-
cellulose (w/v) inwater and 2× Eagles' basal mediumwith Earle's salts
(EBME) supplemented to contain 5% FBS, 1% antibiotics (100 U/ml
penicillin, 100 μg/ml of streptomycin, and 50 μg/ml of gentamicin) was
added to each well. At 48 h post-infection, mediumwas removed and
cells were washed twice with PBS. Cells were then ﬁxed at room
temperature with 1:1 acetone:methanol for 3 m and washed three
times with PBS. After ﬁxation, cells were blocked for 1 h in blocking
buffer (PBS+5% FBS+3% goat serum). After blocking, cells were in-
cubated withMAb-10F10 andMAb-1G10 andMAb-3D7 (anti-Haantan
G2) diluted 1:100 in blocking buffer for 1 h at room temperature. Cells
were then washed three times in PBS and incubated with an anti-
mouse secondary antibody conjugated to Alexaﬂuor488 (Invitrogen,
Carlsbad, CA) (1:500) for 30 min at room temperature. Cells were
washed three more times with PBS, once with distilled water, and
mounted on glass slides using ProLong Gold anti-fade reagent con-
taining DAPI nucleic acid stain (Invitrogen). Samples were then ex-
amined by ﬂuorescence microscopy.
Construction of chimeric A33R plasmids
Replacement of the A33oMPXV terminal threonine with the last ﬁve
amino acids of A33VACV was accomplished by using a 5′ A33RoMPXV
primer (5′-GGGGCGGCCGCATGGTGCCGCAGCAAGCATGACAG-3′ and a
3′ primer homologous to A33RoMPXV but containing the 3′ end of
A33RVACV (5′ GCGCAGATCTTTAGTTCATTGTTTTAACACAAAAATACTTT-
CTAACTTCTTG-3′). These primers incorporated a NotI and BglII re-
striction site (underlined), respectively. The resultant gene product
was cloned into these restriction sites in the pWRG/vector, generating
pWRG/A33RoMP/VACV-Cterm. Site-directed mutagenesis to change
amino acids 117, 118, and 120 of the A33RoMPXV gene was performed
in a two-step PCR reaction. The ﬁrst step consisted of two distinct PCR
reactions that utilized an A33RoMPXV forward (see above) or reverse
(5′-GGGAGATCTTTAGTTCATTGTTTTAACACA-3′) primer combined
with a mutagenic reverse or forward primer listed in Table 1. This
reaction generated two fragments of the A33RoMPXV gene, each con-
taining the desired mutation. To generate full-length A33RoMPXV con-
taining the desired mutations, products from the two reactions were
combined and a ﬁnal PCR reaction using the A33RoMPXV forward and
reverse primers was performed. The forward and reverse primers also
introduced NotI and BglII (underlined) sites to the 5′ and 3′ ends of the
genes, respectively. All PCR reactions were performed using the
Phusion polymerase (New England Biolabs, Ipswich, MA). After PCR,
fragments were digested with NotI and BglII, and ligated into the
pWRG/vector, generating pWRG/A33RoMP117–120. Sequence analysis
was used to verify that the changes had been successfully incor-
porated into the gene. These changes are identical to those of the
predicted amino acid sequence for VACV, strain Connaught, at the
indicated positions.
Flow cytometry
COS cell monolayers (70–80% conﬂuent) were transiently trans-
fected with pWRG/A33R or pMPXV/A33Ro, or the indicated muta-
genized A33RoMPXV constructs using Fugene6. Transfected cells were
incubated at 37 °C for 48 h, trypsinized, and washed once with EMEM.
After the wash, ∼1×106 cells were transferred to 1.5-ml tubes. Cells
Table 1
Primers used for the site-directed mutagenesis of the A33RoMPXV gene
Mutated amino acids Forward primera Reverse primera
K117Q ATTACATTCAGACTATCAGTCATTCGAGGATGCTAAAGCA TGCTTTAGCATCCTCGAATGACTGATAGTCTGAATGTAAT
S118L ATTACATTCAGACTATAAGTTATTCGAGGATGCTAAAGCA TGCTTTAGCATCCTCGAATAACTTATAGTCTGAATGTAAT
E120S ATTACATTCAGACTATAAGTCATTCTCGGATGCTAAAGCA TGCTTTAGCATCCGAGAATGACTTATAGTCTGAATGTAAT
K117Q, S118L ATTACATTCAGACTATCAGTTATTCGAGGATGCTAAAGCA TGCTTTAGCATCCTCGAATAACTGATAGTCTGAATGTAAT
K117Q, E120S ATTACATTCAGACTATCAGTCATTCTCGGATGCTAAAGCA TGCTTTAGCATCCGAGAATGACTGATAGTCTGAATGTAAT
S118L E120S ATTACATTCAGACTATAAGTTATTCTCGGATGCTAAAGCA TGCTTTAGCATCCGAGAATAACTTATAGTCTGAATGTAAT
K117Q, S118L, E120S ATTACATTCAGACTATCAGTTATTCTCGGATGCTAAAGCA TGCTTTAGCATCCGAGAATAACTGATAGTCTGAATGTAAT
a All primers listed in 5′–3′ direction with the position of the mutation(s) underlined.
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for 1 h at room temperature in FACS buffer (PBS, 5% FBS and 0.1%
sodium azide). Alternatively, cells were incubated with serum from
mice vaccinated with A33Ro DNA (1:50). After incubation with the
primary antibody, cells were pelleted by centrifugation at 750 ×g for
3 m and washed twice with PBS. Cells were next incubated with anti-
mouse Alexaﬂuor488 (Invitrogen) (1:500) for 30 min at room tem-
perature. After incubation with the secondary antibody, cells were
pelleted by centrifugation at 750 ×g for 3 min. Washed cells were
resuspended in 1ml of FACS buffer. Flow cytometry was performed on
a FACSCalibur ﬂow cytometer (Becton Dickinson; San Jose, CA). Data
were collected and analyzed using FlowJo software (Tree Star INC;
Ashland, OR). A total of 10,000 cells were analyzed for each sample.
Western blot analysis
COS cell monolayers (70–80% conﬂuent) were transiently trans-
fected with pWRG/A33R, or empty vector using Fugene6. Transfected
cells were incubated at 37 °C for 48 h, after which cells were collected
by centrifugation at 179 ×g, washed twice in chilled PBS, and lysed in
tris lysis buffer (10 mM Tris [pH 7.5], 2.5 mM MgCl2, 100 NaCl, 0.5%
Triton X-100, 5 μg/μl of leupeptin [Sigma], 1 mM PMSF). After centri-
fugation at 179 ×g to remove cellular debris, samples were resus-
pended in protein sample buffer (0.125 M Tris [pH 8.0], 1% SDS, 0.01%
bromphenol blue, 10% sucrose) with or without the addition of 5%
β-mercaptoethanol as indicated. Protein samples then were analyzed
by electrophoresis on SDS-10% polyacrylamide gels and transferred to
nitrocellulose membranes (Bio-Rad Laboratories, Hercules, Calif.).
Nitrocellulose membranes were blocked overnight at 4 °C in tris-
buffered saline (10 mM Tris [pH 8.0], 150 mM NaCl and 0.05% Tween)
(TBS-T) containing 5% nonfat dry milk, rinsed with TBS-T, and
incubatedwithMAb-10F10 orMAb-1G10 (1:1000) for 1 h. Membranes
were subsequently washed with TBS-T and incubated for 1 h with
horseradish peroxidase-conjugated anti-mouse immunogloblin G
(IgG) (1:10000 in TBS-T) (Amersham, Arlington Heights, Ill.). Bound
antibody was detected by treating the nitrocellulose ﬁlters with en-
hanced chemiluminescence (ECL) detection reagents (Amersham) and
exposing the ﬁlters to ﬁlm.
DNA vaccination with gene-gun
The DNA vaccination procedure was described previously (Hooper
et al., 2000; Schmaljohn et al., 1997). Brieﬂy, plasmid DNA pWRG/
A33Ro, pMPXV/A33Ro, or pWRG/HTNG1was precipitated onto∼2-μM
diameter gold beads at a concentration of 1 μg of DNA/1 mg of gold.
DNA-gold mixtures were coated on the inner surface of irradiated
Tefzel tubing and the tubing was cut into 0.5-in cartridges. Each car-
tridge contained ∼0.25–0.5 μg of DNA coated on 0.5 mg of gold. All
cartridges were quality controlled to ensure the presence of DNA. For
vaccinations, the abdominal fur of BALB/c mice was shaved and DNA-
coated gold was administered using a gene-gun (Powdermed delivery
device, Powdermed, INC;Oxford, England) and compressedheliumgas
at 400 p.s.i. Two cartridges were used per mouse at each vaccination.Micewere vaccinated three times at 3-week intervals. All micewere at
least 7–9-weeks old at the start of vaccination.
Scariﬁcation
Scariﬁcation was performed by placing a 10-μl drop of PBS con-
taining 8×106 106 pfu of VACV, strain Connaught, near the base of the
tail on each mouse. The tail was then scratched ∼15–20 times using a
needle on a tuberculin syringe.
Viral challenges
Mice were anesthetized and weighed before intranasal adminis-
trationwith a plastic pipette tip containing 50 μl of PBSwith 2×106 pfu
of VACV, strain IHD-J. This dose represents at least three times the LD50.
Mice were observed and weighed daily for 21 days post-infection.
Moribund mice (N30% body weight) were euthanized.
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